Adamis Pharmaceuticals Corporation Stock News

Gainers Code Chain New Continent Limited (NYSE: CCNC) shares jumped 74% to $0.2868 after declining around 14% on Tuesday. FLJ Group Limited (NASDAQ: FLJ) gained 69% to $2.59. Hempacco Co., Inc. (NAS

Gainers Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) rose 43.2% to $0.2097 in pre-market trading after jumping over 16% on Tuesday. Adamis Pharmaceuticals recently announced a review of strateg

Gainers FedNat Holding Company (NASDAQ: FNHC) shares climbed 107.7% to close at $0.3395 on Tuesday. DICE Therapeutics, Inc. (NASDAQ: DICE) shares gained 62.3% to close at $40.00 after the company an

Gainers LogicBio Therapeutics, Inc. (NASDAQ: LOGC) shares surged 637.6% to close at $2.01 on Monday after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per

SAN DIEGO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in

Adamis Pharmaceuticals recently provided an update on Tempol's Phase II/III COVID-19 trial, which revealed the interim did not demonstrate statistical significance of its primary endpoint. The DSMB ha

Gainers Stabilis Solutions, Inc. (NASDAQ: SLNG) shares climbed 71.3% to close at $8.84 after the company announced it has received authorization from the U.S. Department of Energy to export domestic

U.S. stocks traded slightly higher toward the end of trading session on Wednesday following the announcement of interest rate decision by the Fed. The Dow traded up 0.06% to 30,725.62 while the NASDAQ

Gainers Stabilis Solutions, Inc. (NASDAQ: SLNG) shares jumped 108% to $10.73 after the company announced it has received authorization from the U.S. Department of Energy to export domestically produ

U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 100 points on Wednesday. The Dow traded up 0.40% to 30,829.94 while the NASDAQ rose 0.31% to 11,460.00. The S&P 5

SAN DIEGO, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that the third planned interim analysis of the Phase 2/3 clinical trial examining the

The clinical trial of Tempol has reached the initial planned enrollment of 248 subjects

Meeting adjourned only with respect to reverse stock split proposal until September 8, 2022 Meeting adjourned only with respect to reverse stock split proposal until September 8, 2022

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP ) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Robert Uhl - Managing Director, ICR Westwicke David J. Marguglio - Ch

SAN DIEGO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid over